Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
Immunotherapy Combined with Stereotactic Radiation in Early-Stage, Medically Inoperable NSCLC: Safety Analysis from I-SABR
ASCO 2020 - Lung Cancer
Conference Correspondent
— May 30, 2020
Stereotactic ablative radiotherapy combined with immunotherapy (I-SABR) is well-tolerated in patients with early-stage, medically inoperable, isolated-recurrence non–small-cell lung cancer without lymph node or distant metastasis.
Read Article
Meta-analysis of Checkpoint Inhibitor Trials in Front-Line NSCLC
ASCO 2020 - Lung Cancer
Conference Correspondent
— May 30, 2020
Based on a meta-analysis of randomized trials in the first-line treatment of non–small-cell lung cancer, adding chemotherapy to immune checkpoint inhibitors (ICIs) improves response rates and progression-free survival in some patients compared with ICI monotherapy, but does not confer an overall survival benefit regardless of PD-L1 status.
Read Article
Phase 2 Study of Nivolumab with Gemcitabine/Cisplatin or Ipilimumab as First-Line Therapy for Patients with Advanced Unresectable BTC (BilT-01)
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
— May 30, 2020
The combinations of nivolumab with gemcitabine/cisplatin or nivolumab with ipilimumab were tested in patients with untreated advanced biliary tract cancer.
Read Article
Combination Immunotherapy with Ipilimumab and Nivolumab in Patients with Advanced Biliary Tract Cancer
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
— May 30, 2020
The response rate to the combination of ipilimumab and nivolumab in patients with advanced biliary tract cancer compared favorably to clinical trials investigating single-agent anti–PD-1 therapy.
Read Article
Phase 2 Study Assessing Tolerability, Efficacy, and Biomarkers for Durvalumab ± Tremelimumab and Gemcitabine/Cisplatin in Chemo-Naïve Advanced BTC
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
— May 30, 2020
Durvalumab ± tremelimumab plus chemotherapy was well-tolerated and showed promising efficacy in chemotherapy-naïve patients with advanced biliary tract cancer.
Read Article
IDH1 Mutation Detection in ctDNA and Association with Clinical Response in Patients with Advanced iCCA from Phase 3 ClarIDHy
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
— May 30, 2020
Detection of
IDH1
mutations in plasma from patients with intrahepatic cholangiocarcinoma is highly concordant with detection in tumor tissue.
Read Article
Adjuvant Concurrent Chemoradiotherapy in Extrahepatic Cholangiocarcinoma
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
— May 30, 2020
The use of adjuvant chemoradiotherapy was associated with improved overall survival compared with chemotherapy alone in patients with resected extrahepatic cholangiocarcinoma.
Read Article
Retrospective Analysis of Post Second-Line Chemotherapy Outcomes with Advanced or Metastatic CCA and FGFR2 Fusions
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
— May 28, 2020
In a phase 2 trial of patients with cholangiocarcinoma and
FGFR2
fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit.
Read Article
FOENIX-CCA2: Phase 2, Open-Label, Multicenter Study of Futibatinib in Patients with iCCA Harboring FGFR2 Gene Fusions
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
— May 28, 2020
Preliminary data are reported for a phase 2, open-label multicenter study of futibatinib in patients with intrahepatic cholangiocarcinoma harboring
FGFR2
gene fusions or other rearrangements.
Read Article
Natural History of Fibroblast Growth Factor Receptor–Altered Cholangiocarcinoma
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
— May 28, 2020
The clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations are reported based on a retrospective chart review.
Read Article
Page 9 of 44
4
5
6
7
8
9
10
11
12
13
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma